MedTrace Logo

Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

NCT04314817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-04-21

No results posted yet for this study

Summary

The outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Conditions

Interventions

DRUG

Any drug used to treat Covid-19

lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.

Sponsors & Collaborators

  • CMC Ambroise Paré

    collaborator OTHER

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Principal Investigators

  • Joe-Elie Salem, MD, PhD · Clinical Investigations Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-17
Primary Completion
2023-01-01
Completion
2023-01-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314817 on ClinicalTrials.gov